Oncolytics Biotech Inc ONCY

ONCY's acquirer interested in breast, pancreatic, and GI CA

[Noteable]

Big Pharma companies in Breast, Pancreatic and GI cancers would be seeking to use pelareorep in combination with immune checkpoint inhibitors, small molecules PARP and CDK 4/6 inhibitors, bispecifics and ADCs, and CAR-T therapy in solid tumors. Those are just a few reasons why Big Pharma companies are eagerly speaking with ONCY.

[Snowdrift]

I sure hope you're right.  Oncy says it's well underway toward a Phase 3 registrational study, but where do they say that big pharma companies are eagerly speaking with them? Why do you think the stock is tanking today?  Profit taking?  Disappointment over the fact that Oncy is talking about a partnership rather than a buyout?  Something else altogether? Snowdrift

[Noteable]

"BRACELET-1's data greatly enhance our pipeline's value proposition, bringing our breast cancer program to pivotal trial-readiness and confirming pelareorep's potential to address large markets by synergistically combining with other anti-cancer agents. Looking ahead, we believe our data in breast cancer, together with the second registration opportunity offered by our

[Noteable]

Those manipulating the stock price "want in" and "want all" as armedescapade on Yahoo once admitted.